Modern Diagnostic & Research Centre Limited

As of March 31, 2026, Modern Diagnostic & Research Centre Limited carries a market capitalization of 809.62M, placing it among publicly traded companies globally. Its enterprise value stands at 1.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Modern Diagnostic & Research Centre Limited has 15.10M shares outstanding.

As of March 31, 2026, Modern Diagnostic & Research Centre Limited trades at a trailing price-to-earnings ratio of 15.41. The price-to-sales ratio is 0.97, and the price-to-book ratio stands at 1.38.

As of March 31, 2026, Modern Diagnostic & Research Centre Limited trades at an EV/EBITDA multiple of 8.48 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.09B versus a market cap of 809.62M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Modern Diagnostic & Research Centre Limited maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.36, indicating elevated leverage, while an interest coverage ratio of 5.25 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Modern Diagnostic & Research Centre Limited posted a return on equity (ROE) of 13.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.74, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.67, useful for judging operating efficiency across full business cycles. The company generates approximately 1.36M in revenue per employee across its workforce of 612.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.48 indicates how many times Modern Diagnostic & Research Centre Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Modern Diagnostic & Research Centre Limited recorded 7.38M in income tax expense. That works out to an effective tax rate of 12.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 59.91M, leaving 52.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026.

Over the twelve months ended March 31, 2026, Modern Diagnostic & Research Centre Limited generated 831.11M in revenue and converted that into 52.53M in net income, yielding earnings per share of 3.48. EBITDA reached 128.20M, while operating income came in at 77.49M.

As of March 31, 2026, Modern Diagnostic & Research Centre Limited holds 94.00M in cash and equivalents against 370.97M in total debt, resulting in a net debt position of 276.97M. Total book value stands at 585.47M, with working capital of -914,000.00 providing operational flexibility.

Modern Diagnostic & Research Centre Limited produced 38.24M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -236.97M in capital expenditures, free cash flow totaled -198.73M - equivalent to -13.16 per share.

Over the twelve months ended March 31, 2026, Modern Diagnostic & Research Centre Limited posted a gross margin of 67.63, reflecting its pricing power and cost economics. The operating margin of 9.32 and net profit margin of 6.32 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -24.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -55.69, meaning Modern Diagnostic & Research Centre Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Modern Diagnostic & Research Centre Limited has an Altman Z-Score of 1.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.